NDAORALTABLET
Approved
Aug 2019
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
17
Mechanism of Action
Parkinson's disease is unknown. In in vitro studies and in in vivo animal studies, istradefylline was demonstrated to be an adenosine A 2A receptor antagonist.
Clinical Trials (5)
Istradefylline Effect Protocol on Parkinson's Disease Tremor
Started Jan 2023
27 enrolled
Parkinson DiseaseTremor
Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
Started Jul 2022
8 enrolled
ApathyParkinson Disease
Istradefylline for Parkinson Disease With Cognitive Impairment
Started Jul 2022
15 enrolled
Parkinson DiseaseCognitive Impairment
A Study to Evaluate Abuse Potential of Istradefylline
Started Jan 2016
42 enrolled
Drug Abuse
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Started Dec 2015
239 enrolled
Idiopathic Parkinson's Disease
Loss of Exclusivity
LOE Date
Jan 28, 2028
23 months away
Patent Expiry
Jan 28, 2028